Clinical trials: Cancer, Hepatocellular
To Predict Early Post-hepatectomy Mortality for HCC
Calculator Predicts Early Mortality Post Hepatocellular Carcinoma Resection
Using the multicenter data, we developed and validated an individualized online calculator to predict early mortality after liver resection for hepatocellular carcinoma.
- Trial name
- NCT06621485
- Where
- China
- Volunteers
- 4,966 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Solid Tumors, Hepatocellular Carcinoma (HCC)
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5).
- Conditions
- Solid Tumors, Hepatocellular Carcinoma (HCC), Malignant Melanoma, Pediatric Cancer
- Trial name
- NCT06636435
- Testing
- CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3
- Where
- 5 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Chiome Bioscience Inc.
Hepatocellular Carcinoma
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
This is a Phase I study, which means that the goal is to see if the combination of Temsirolimus and Sorafenib is safe in patients with Hepatocellular Carcinoma. Sorafenib is a standard treatment for Hepatocellular Carcinoma.
- Trial name
- NCT01008917
- Testing
- sorafenib with temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Hepatocellular Carcinoma
AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601)
This study aims to prospectively validate a retrospective cohort-derived AI-based multimodal model and explore tumor heterogeneity and the immune microenvironment to guide TACE combined with immunotherapy and targeted therapy in…
- Trial name
- NCT07584317
- Testing
- Artificial Intelligence
- Volunteers
- 1,170 people
- Sponsor
- Gao-jun Teng
Sarcopenia, Hepatocellular Carcinoma
Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular Carcinoma
It is known that some substances present in the blood, called 'myokines,' influence muscle loss. Some may accelerate this loss, while others may prevent it. Inflammatory substances in the blood can also contribute to muscle loss.
- Trial name
- Myomachia (NCT06475118)
- Testing
- Dynamometry measurement, myokine dosing, sarcopenia calculation
- Where
- France
- Volunteers
- 139 people
- Sponsor
- CHU de Reims
Arthritis of Knee, Arthritis of Hip
Comparison of the Diagnosis Time of VET and SCL in Patients With Intraoperative Coagulopathy
The present study is a prospective, multi-center observational trial comparing the times taken to diagnose coagulopathies using point-of-care (POC) viscoelastic tests or standard central laboratory tests (SCL tests) in patients…
- Conditions
- Arthritis of Knee, Arthritis of Hip, Spine, Prostate Cancer
- Trial name
- NCT06637943
- Testing
- SCL tests, POC viscoelastic tests
- Where
- 4 sites in South Korea
- Volunteers
- 210 people
- Sponsor
- Konkuk University Medical Center
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Liver Transplant; Complications, Transplant; Failure, Liver
Liver Transplantation After ex Vivo Liver Perfusion
Today, it is difficult to predict liver function after transplantation and therefore livers where poor function is assumed (marginal livers) become discarded.
- Conditions
- Liver Transplant; Complications, Transplant; Failure, Liver, Transplant Dysfunction, Transplant; Complication, Rejection
- Trial name
- EVOLVE (NCT05951231)
- Testing
- Liver transplantation
- Volunteers
- 22 people
- Sponsor
- Oslo University Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with liver…
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00003296
- Testing
- filgrastim, pegylated liposomal doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Brown University
Liver Cancer
Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
The goal of this clinical research study is to find the highest tolerable dose of the combination of everolimus with TheraSphere that can be given to patients with advanced NETs that have spread to the liver.
- Trial name
- NCT01864070
- Testing
- TheraSphere, Everolimus, Phone Call
- Sponsor
- M.D. Anderson Cancer Center
Liver Carcinoma
CIRSE Registry for SIR-Spheres Therapy
The administration of SIR-Spheres microspheres (yttrium-90 resin microspheres) is a form of selective internal radiation therapy (SIRT) for the treatment of patients with primary and secondary liver tumours.
- Trial name
- CIRT (NCT02305459)
- Testing
- Yttrium-90 loaded SIR-Spheres microspheres, QLQ-C30 with HCC module
- Where
- Austria
- Volunteers
- 1,051 people
- Sponsor
- Cardiovascular and Interventional Radiological Society of Europe
Fibrolamellar Hepatocellular Carcinoma
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
The purpose of this study is to determine whether the combination of subcutaneous DRP-104 in combination with intravenous Durvalumab is safe and yields a clinically compelling antitumor activity measured as based on objective…
- Trial name
- NCT06027086
- Testing
- Durvalumab, DRP-104
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Solid Tumor, Lung Squamous Cell Carcinoma
JMT106 Injection in the Treatment of Advanced Solid Tumors
This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT07275073
- Testing
- JMT106 Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai JMT-Bio Inc.
Hepatocellular Carcinoma, Cholangiocarcinoma
Open Versus Laparoscopic Ablation of Liver Malignancies
The purpose of this study is to compare laparoscopic ablation to open ablation of liver malignancies regarding complication rates and ablation response as well as quality of life following the surgery.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Liver Metastases
- Trial name
- OPTIMAL (NCT06304766)
- Testing
- Laparoscopic ablation, Open ablation
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hepatocellular Carcinoma, Esophagogastric Varices
Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular Carcinoma
The study is aimed to explore the efficacy of transarterial chemoembolization (TACE) combined with endoscopic therapy for unresectable hepatocellular carcinoma (HCC) complicated with esophagogastric varices (EGV) and seek out…
- Trial name
- NCT05017922
- Testing
- transarterial chemoembolization combined with endoscopic therapy
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Qilu Hospital of Shandong University
Hepatocellular Carcinoma
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
The primary efficacy endpoint will be the proportion of subjects that remain free of progression at the 27th week following the onset of treatment.
- Trial name
- NCT00287222
- Testing
- Bevacizumab, Erlotinib
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Arkansas
Hepatocellular Carcinoma, Donafenib
A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC
This study is a prospective, single-center, observational real-world study. It is planned to enroll 150 patients with unresectable hepatocellular carcinoma treated with Donafenib combined with TACE-based treatment, so as to…
- Trial name
- NCT05205629
- Testing
- Donafenib combined with TACE
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Zhongshan Hospital
Cancer of Head and Neck, Lung Cancer, Nonsmall Cell
A Multicenter Cancer Biospecimen Collection Study
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor…
- Conditions
- Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT04510129
- Testing
- OncoPrism™ assay
- Where
- United States
- Volunteers
- 1,650 people
- Sponsor
- Cofactor Genomics, Inc.
Recurrent Colon Cancer, Liver Metastases
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Conditions
- Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00019760
- Testing
- floxuridine, leucovorin calcium, melphalan
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of dasatinib in treating patients with solid tumors or lymphomas that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, Adult Hepatocellular Carcinoma, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
- Trial name
- NCT00608361
- Testing
- Dasatinib, Pharmacological Study
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)